Article No
SYN-1001-M001
Specifications
| CAS No | 852808-04-9 |
| MW | 813.4 |
| Article No | SYN-1001-M001 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT |
| Description | ABT-737 |
| Supplier | Adipogen Life Sciences |
| Format | Powder |
| Notes | ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice. ABT-737 binds to Bcl-2, Bcl-xL and Bcl-w with very high affinities (Ki <1 nM) and also shows a very high specificity over Mcl-1 and A1.|Chemical. CAS: 852808-04-9. Formula: C42H45ClN6O5S2. MW: 813.4. ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice. ABT-737 binds to Bcl-2, Bcl-xL and Bcl-w with very high affinities (Ki <1 nM) and also shows a very high specificity over Mcl-1 and A1. |
| Molecular Formula | C42H45ClN6O5S2 |
| Alias Names | ABT737 |
| Product Type | Chemicals & Biochemicals |
| Purity | >95% |
| Research area | Cell Death |
| Shipping Information | RT |
| Size | 1 mg |
| Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
| Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Storage | -20°C, 4°C |
| Technical Specifications | Chemical. CAS: 852808-04-9. Formula: C42H45ClN6O5S2. MW: 813.4. ABT-737 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-X(L) and Bcl-w, with an affinity two to three orders of magnitude more potent than previously reported compounds. Mechanistic studies reveal that ABT-737 does not directly initiate the apoptotic process, but enhances the effects of death signals, displaying synergistic cytotoxicity with chemotherapeutics and radiation. ABT-737 exhibits single-agent-mechanism-based killing of cells from lymphoma and small-cell lung carcinoma lines, as well as primary patient-derived cells, and in animal models, ABT-737 improves survival, causes regression of established tumors, and produces cures in a high percentage of the mice. ABT-737 binds to Bcl-2, Bcl-xL and Bcl-w with very high affinities (Ki <1 nM) and also shows a very high specificity over Mcl-1 and A1. |
| Product Page Updated | 2024-02-01T08:25:01.492Z |
